On March 12, 2019, based on the Nominating and Corporate Governance Committee’s recommendation, the Board of Bellerophon Therapeutics, Inc. appointed Crispin Teufel as a director effective March 18, 2019 to represent Linde North America, Inc. (“Linde”), fourth largest shareholder. Jens Luehring, who has recently left Linde to become CEO of a newly formed spin off company, will not stand for reelection at annual meeting of stockholders and will be succeeded by Mr. Teufel. Additionally, Mr. Daniel Tassé has recently assumed new CEO responsibilities that require him to step down from Board and will also not stand for reelection. Messrs. Tassé and Luehring will continue to serve as members of board of directors until their terms expire at the conclusion of the annual meeting of stockholders.